Boston Scientific Corporation has agreed to acquire Penumbra, Inc. in a cash-and-stock transaction valuing Penumbra at $374 per share. The deal implies an enterprise value of approximately $14.5 billion.
Strategic Rationale Behind the Acquisition
Boston Scientific sees the deal as a gateway into fast-growing vascular segments. Penumbra brings:
- A proven innovation engine
- Strong revenue growth
- Leadership in thrombectomy and neurovascular care
Mike Mahoney, Chairman and CEO of Boston Scientific, highlighted the cultural and strategic fit. Penumbra CEO Adam Elsesser will join Boston Scientific’s board after closing.
Why Penumbra Matters?
Cardiovascular disease remains the leading global cause of death. Penumbra has built a differentiated portfolio addressing:
- Pulmonary embolism
- Ischemic stroke
- Deep vein thrombosis
- Acute limb ischemia
- Heart attack
- Aneurysms
Its technologies focus on restoring blood flow and removing clots rapidly.
Penumbra’s Core Technology Portfolio
Mechanical Thrombectomy
Penumbra is best known for its mechanical thrombectomy systems, including:
- Lightning Bolt
- Lightning Flash
These are computer-assisted vacuum thrombectomy (CAVT) platforms. They are used across arterial, venous, and pulmonary vessels.
Peripheral Embolization
The company also offers:
- A minimally invasive embolization system
This system is designed to:
- Control haemorrhaging
- Stop bleeding
- Close targeted blood vessels
Neurovascular Solutions
Penumbra’s neurovascular portfolio includes:
- Stroke revascularization
- Neuro embolization
- Access solutions
The company continues to expand clinical evidence to support broader adoption.
Financial Performance Snapshot
Penumbra expects:
- Q4 revenue growth: ~21.4%–22.0%
- FY2025 revenue: ~$1.4 billion
This represents 17.3%–17.5% year-over-year growth. The company continues to invest in multi-year R&D and clinical programs.
Deal Structure and Consideration
Under the agreement:
- Shareholders may receive $374 in cash
- Or 3.8721 Boston Scientific shares
The final mix will be:
- ~73% cash
- ~27% stock
Adam Elsesser plans to take Boston Scientific shares for all his holdings.
Financing and Earnings Impact
Boston Scientific will fund the ~$11 billion cash portion using:
- Cash on hand
- New debt
Earnings impact expectations:
- Year 1: $0.06–$0.08 dilutive (adjusted EPS)
- Year 2: Neutral to slightly accretive
- Beyond: Increasingly accretive
GAAP EPS dilution will ease over time due to amortization effects.
Timeline and Advisors
The transaction is expected to close in 2026, subject to:
- Penumbra shareholder approval
- Regulatory and customary closing conditions
Advisors involved:
- Boston Scientific: Allen Overy Shearman & Sterling, Arnold & Porter
- Penumbra: Perella Weinberg Partners, Davis Polk & Wardwell
Bottom Line
This acquisition strengthens Boston Scientific’s position in vascular and neurovascular care. Penumbra adds:
- High-growth revenue
- Market-leading thrombectomy platforms
- A deep pipeline of innovation
For Boston Scientific, this is a long-term bet on complex vascular disease treatment at global scale.
